Ascendis Pharma (ASND)
238.90
0.00 (0.00%)
Upcoming Events
Latest Headlines
RBC Capital names top healthcare stocks as sector upgraded to overweight
October 20, 2026 4:05 PM - StreetInsider
Form 6-K Ascendis Pharma A/S For: Oct 16
October 16, 2026 2:59 PM - SEC Filing
EU panel recommends Ascendis Pharma's navepegritide for achondroplasia
October 16, 2026 8:30 AM - StreetInsider
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
October 16, 2026 8:29 AM - Globe NewsWire
Ascendis Pharma (ASND) PT Lowered to $269 at UBS
October 15, 2026 9:21 AM - StreetInsider
Form 6-K Ascendis Pharma A/S For: Oct 14
October 14, 2026 5:02 PM - SEC Filing
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
October 6, 2026 9:15 AM - Globe NewsWire
Form 6-K Ascendis Pharma A/S For: Sep 29
September 29, 2026 4:03 PM - SEC Filing
Form 4 Ascendis Pharma A/S For: Apr 14 Filed by: BIENAIME JEAN JACQUES
September 28, 2026 4:08 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)
September 16, 2026 6:55 AM - StreetInsider
Ascendis Pharma (ASND) call put ratio 1 call to 1 put a share price down 12.6%
September 15, 2026 1:57 PM - StreetInsider
Form 6-K Ascendis Pharma A/S For: Sep 14
September 15, 2026 6:06 AM - SEC Filing
Form 6-K Ascendis Pharma A/S For: Sep 14
September 15, 2026 6:06 AM - SEC Filing
Raymond James Downgrades Ascendis Pharma (ASND) to Outperform
September 15, 2026 3:25 AM - StreetInsider
Ascendis Pharma board approves $400M share repurchase program
September 14, 2026 6:00 PM - StreetInsider
Ascendis Announces Planned $400 Million Share Repurchase Program
September 14, 2026 6:00 PM - Globe NewsWire
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
September 14, 2026 6:00 PM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)
September 10, 2026 6:48 AM - StreetInsider
TD Cowen on Ascendis Pharma (ASND): 'encouraging'
September 10, 2026 5:05 AM - StreetInsider
BMO Capital Reiterates Outperform Rating on Ascendis Pharma (ASND)
September 10, 2026 2:56 AM - StreetInsider
Ascendis Pharma reports 52-week infant data for TransCon CNP trial
September 9, 2026 4:02 PM - StreetInsider
Ascendis Pharma (ASND) PT Raised to $312 at Oppenheimer
September 1, 2026 4:04 PM - StreetInsider
Ascendis Pharma (ASND) PT Lowered to $273 at Morgan Stanley
September 1, 2026 8:07 AM - StreetInsider
Ascendis Pharma (ASND) PT Lowered to $304 at BofA Securities
September 1, 2026 6:59 AM - StreetInsider
Ascendis Pharma (ASND) PT Lowered to $330 at Jefferies
August 31, 2026 8:51 AM - StreetInsider
Ascendis Pharma (ASND) PT Lowered to $326 at Stifel
August 31, 2026 8:10 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)
August 31, 2026 6:49 AM - StreetInsider
H.C. Wainwright Starts Ascendis Pharma (ASND) at Buy
August 27, 2026 6:12 AM - StreetInsider
Ascendis to present 2-year navepegritide trial data at ISDS 2026
August 25, 2026 4:01 PM - StreetInsider
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
August 25, 2026 4:01 PM - Globe NewsWire
Form 4 Ascendis Pharma A/S For: Aug 14 Filed by: BIENAIME JEAN JACQUES
August 18, 2026 9:03 PM - SEC Filing
BMO Capital Starts Ascendis Pharma (ASND) at Outperform
August 18, 2026 4:13 PM - StreetInsider
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
August 18, 2026 8:00 AM - StreetInsider
Ascendis Pharma (ASND) PT Raised to $341 at TD Cowen
August 14, 2026 8:50 AM - StreetInsider
Ascendis Pharma (ASND) PT Raised to $290 at RBC Capital
August 14, 2026 8:41 AM - StreetInsider
Ascendis Pharma (ASND) PT Lowered to $329 at Barclays
August 14, 2026 4:20 AM - StreetInsider
Form SCHEDULE 13G/A Ascendis Pharma A/S Filed by: Artisan Partners Limited Partnership
August 13, 2026 4:31 PM - SEC Filing
Ascendis Pharma (ASND) PT Raised to $360 at Citi
August 13, 2026 4:08 PM - StreetInsider
Ascendis Pharma (ASND) PT Raised to $333 at Jefferies
August 13, 2026 4:03 PM - StreetInsider
Form 6-K Ascendis Pharma A/S For: Aug 13
August 13, 2026 9:14 AM - SEC Filing
Form 6-K Ascendis Pharma A/S For: Jun 30
August 13, 2026 7:56 AM - SEC Filing
Ascendis Pharma (ASND) Tops Q2 EPS by 132c
August 13, 2026 7:41 AM - StreetInsider
Ascendis Pharma Reports Second Quarter 2026 Financial Results
August 13, 2026 7:30 AM - Globe NewsWire
Form 6-K Ascendis Pharma A/S For: Aug 12
August 12, 2026 5:16 PM - SEC Filing
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
August 6, 2026 4:01 PM - Globe NewsWire
Form 6-K Ascendis Pharma A/S For: Aug 06
August 6, 2026 11:55 AM - SEC Filing
Ascendis reports COACH trial Week 78 data and Yuviwel uptake
August 6, 2026 8:01 AM - StreetInsider
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
August 6, 2026 8:00 AM - Globe NewsWire
Full Article List
